Background: The U.S. Preventive Services Task Force recommends against routine screening for colorectal cancer (CRC) in adequately screened persons older than 75 years but does not address the appropriateness of screening in elderly persons without previous screening.
Objective: To determine at what ages CRC screening should be considered in unscreened elderly persons and to determine which test is indicated at each age.
Design: Microsimulation modeling study.
Data Sources: Observational and experimental studies.
Target Population: Unscreened persons aged 76 to 90 years with no, moderate, and severe comorbid conditions.
Time Horizon: Lifetime.
Perspective: Societal.
Intervention: One-time colonoscopy, sigmoidoscopy, or fecal immunochemical test (FIT) screening.
Outcome Measures: Quality-adjusted life-years gained, costs, and costs per quality-adjusted life-year gained.
Results Of Base-case Analysis: In unscreened elderly persons with no comorbid conditions, CRC screening was cost-effective up to age 86 years. Screening with colonoscopy was indicated up to age 83 years, sigmoidoscopy was indicated at age 84 years, and FIT was indicated at ages 85 and 86 years. In unscreened persons with moderate comorbid conditions, screening was cost-effective up to age 83 years (colonoscopy indicated up to age 80 years, sigmoidoscopy at age 81 years, and FIT at ages 82 and 83 years). In unscreened persons with severe comorbid conditions, screening was cost-effective up to age 80 years (colonoscopy indicated up to age 77 years, sigmoidoscopy at age 78 years, and FIT at ages 79 and 80 years).
Results Of Sensitivity Analyses: Results were most sensitive to assuming a lower willingness to pay per quality-adjusted life-year gained.
Limitation: Only persons at average risk for CRC were considered.
Conclusion: In unscreened elderly persons CRC screening should be considered well beyond age 75 years. A colonoscopy is indicated at most ages.
Primary Funding Source: National Cancer Institute.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109030 | PMC |
| http://dx.doi.org/10.7326/M13-2263 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends, characteristics, and outcomes of pregnancy in women with attention-deficit hyperactivity disorder: A nationwide analysis.
Eur J Obstet Gynecol Reprod Biol
January 2025
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Los Angeles General Medical Center, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address:
Objective: To assess clinical and obstetric characteristics associated with pregnant patients with a diagnosis of attention-deficit hyperactivity disorder (ADHD).
Methods: This serial cross-sectional study queried the Agency of Healthcare Research and Quality's Healthcare Cost and Utilization Project National Inpatient Sample. The study population was 16,759,786 hospital deliveries from 2016 to 2020.
The Association of Psychological Factors With Willingness to Share Health-Related Data From Technological Devices: Cross-Sectional Questionnaire Study.
JMIR Form Res
January 2025
Department of Medical and Clinical Psychology, Center of Research on Psychological Disorders and Somatic Diseases (CoRPS), Tilburg University, Tilburg, the Netherlands, 31 134662142.
Background: Health-related data from technological devices are increasingly obtained through smartphone apps and wearable devices. These data could enable physicians and other care providers to monitor patients outside the clinic or assist individuals in improving lifestyle factors. However, the use of health technology data might be hampered by the reluctance of patients to share personal health technology data because of the privacy sensitivity of this information.
View Article and Find Full Text PDFAre glucagon-like-peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD). Does the clinical trial with lixisenatide add anything?
Expert Opin Investig Drugs
January 2025
School of Pharmacy and Medical Sciences, Griffith University, Brisbane, Australia.
Introduction: Parkinson's disease (PD) is a common neurodegenerative disease. Glucagon-Like-Peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD, and are being considered for the treatment of PD.
Areas Covered: A phase 2 clinical trial of lixisenatide, a GLP-1 receptor agonist, in the early stages of PD.
Evaluation of dry eye parameters and meibomian gland function using the Lipiscan system in male androgenetic alopecia patients.
Clin Exp Optom
January 2025
Department of Ophthalmology, Giresun University, Giresun, Turkey.
Clinical Relevance: The prevalence of male androgenetic alopecia is increasing worldwide. Evaluation of dry eye parameters and meibomian glands of male androgenetic alopecia patients may help to better understand the effect of this disease on dry eye and to provide appropriate treatment for these patients.
Background: The aim of this work is to evaluate the relationship between male androgenetic alopecia, dry eye, and meibomian gland function.
Vascular endothelial growth factor immunoexpression in oral paracoccidioidomycosis.
Med Oral Patol Oral Cir Bucal
January 2025
School of Dentistry. Federal University of Alfenas Rua Gabriel Monteiro da Silva, 700. Centro 37130.001. Alfenas, Minas Gerais, Brazil
Background: Paracoccidioidomycosis (PCM) is a systemic mycosis endemic and limited to Latin America. Brazil is responsible for more than 80% of diagnosed cases in the world. Since PCM is not a notifiable disease, there are still no accurate data on its incidence in Brazil.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!